Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer

British Journal of Cancer

Volumn 93, Issue 8, 2005, Pages 884-889

  Tsukuda, M ^a   Kida, A ^b   Fujii, M ^c   Kono, N ^d   Yoshihara, T ^e   Hasegawa, Y ^f   Sugita, M ^g  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^d KYORIN UNIVERSITY   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g TOHO UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; Advanced head and neck cancer; Feasibility study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG INDUCED DISEASE; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; MALE; MEDICAL RECORD; MORBIDITY; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN DISEASE; SKIN PIGMENTATION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TIME SERIES ANALYSIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PYRIDINES; TEGAFUR; TREATMENT OUTCOME;

EID: 27144441763     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602804     Document Type: Article

References (29)

1. Akasu T, Moriya Y, Yoshida S, Shirao K, Ohashi Y, Kodaira S, NSAS-CC Group (2004) Adjuvant oral and tegafur (UFT) improves survival after complete mesorectal excision (ME) for pathologic TNM stage III rectal cancer (RC): results of the national surgical adjuvant study (NSAS) - colorectal cancer (CC) 01 randomized trial. Proc Am Soc Clin Oncol 23: 251 (Abstr. 3524)
2. Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, Rosen FR, Javanovic B, Vokes EE (2004) Competing of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 10: 1956-1962
3. Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen F, Mittal BB, Pelzer H, Fung BB, Witt ME, Wenig B, Portugal L, Weichselbaum RW, Vokes EE (2004) Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 15: 1179-1186
4. Cohen EEW, Lingen MW, Vokes EE (2004) The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 22: 1743-1752
5. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KSC, Schultz CJ, Lee N, Fu KK, the Radiation Therapy Oncology Group 9501/Intergroup (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350: 1937-1944
6. Ervin TJ, Clark JR, Weichselbaum RR, Fallon BG, Miller D, Fabian RL, Posner MR, Norris Jr CM, Tuttle SA, Schoenfeld DA (1987) An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 5: 10-20
7. Forastiere AA, Goepfert H, Maor M, Pajak TK, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Perers G, Lee DJ, Leaf A, Ensley J, Cooper J (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098
8. Fujii M, Endo S, Tomita K, Nishijima W, Tsukuda M, Hasegawa Y, Ishitoya J, Ymane H, Fujii H, Honma A, Tomita T (2005) A phase I/II study of S-1 plus cisplatin (CDDP) in patients with head and neck cancer (HNC). Proc Am Soc Clin Oncol 24: 513 (Abstr. 5552)
9. Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M (2003) Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. The Dana Farber Cancer Institute Experience. Cancer 97: 412-418
10. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B (2001) Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 28: 1381-1390
11. Jacobs C, Makuch R (1990) Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: A subset analysis of the Head and Neck Contacts Program. J Clin Oncol 8: 838-847
12. Johnson JT, Wagner RL, Myers EN (1996) A-long term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous carcinoma of the head and neck. Cancer 77: 181-185
13. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, Ohta M (2004) A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-1721
14. Kinoshita T, Nakajima T, Ohashi Y, National Surgical Adjuvant Study Group for Gastric Cancer (N-SAS-GC) (2005) Adjuvant chemotherapy with uracil-tegafur (UFT) for serosa negative advanced gastric cancer: results of a randomized trial by national surgical adjuvant study of gastric cancer. Proc Am Soc Clin Oncol 24: 313 (Abstr. 4021)
15. Kinoshita T, Nashimoto A, Yamamura Y, Okamura T, Sasako M, Sakamoto J, Kojima H, Hiratusuka M, Arai K, Sairenji M, Fukushima N, Kimura H, Nakajima T (2004) Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Gastric Cancer 7: 104-109
16. Koizumi W, Kurihara M, Nakano S, Hasegawa K, The S-1 Cooperative Gastric Cancer Study Group (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58: 191-197
17. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49: 8-31
18. Laramore GE, Scott CB, Al-Sarraf M, Haselow RE, Ervin TJ, Wheeler R, Jacobs JR, Schuller DE, Gahbauer RA, Schwade JG, Cambell BH (1992) Adjuvant chemotherapy for respectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys 23: 705-713
19. Monnerat C, Faivre S, Temam S, Bourhis J, Raymond E (2002) End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 13: 995-1006
20. Nagashima F, Ohtsu A, Yoshida S, Ito K (2005) Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 8: 6-11
21. Noguchi S, Koyama H, Uchino J, Uchino J, Abe R, Miura S, Sugimachi K, Akazawa K, Abe O (2005) Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials. J Clin Oncol 23: 2172-2184
22. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T, the S-1 Cooperative Colorectal Carcinoma Study Group (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 83: 141-145
23. Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet 355: 949-955
24. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 MTegafur-0.4 MGimestat-1 M Otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720
25. Schoffski P (2004) The modulated oral fluropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Dugs 15: 85-106
26. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M (1996a) Antitumor activity of 1 Mtegafur-0.4 M5-chloro-2,4-dihydoxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606
27. Shirasaka T, Shimamoto Y, Ohshima H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996b) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557
28. Tsukuda M, Ogasawara H, Kaneko S, Komiyama S, Horiuchi M, Inuyama Y, Uemura T, Uchida M, Kamata S, Okuda M (1994) A prospective randomized trial of adjuvant chemotherapy with UFT for head and neck carcinoma. Head and Neck UFT Study Group. Gan To Kagaku Ryoho 21: 1169-11177
29. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C (2004) Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91: 1769-1774